Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat in Refractory MDS
NCT00594230Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2008
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of panobinostat in myelodysplastic syndrome (MDS) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Overall Response Rate at 24 months. Started Jan 2008; status: terminated.
02
Drugs
panobinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00594230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00594230.